Related Experiment Video
Updated: Jun 28, 2026

Acupuncture in a Rat Model of Asthma
Published on: August 25, 2020
RhoA/Rho-kinase as a therapeutic target in asthma
1Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan. hkume@med.nagoya-u.ac.jp
Abstract:
Rho-kinase is an effector molecule of RhoA, a monomeric GTP-binding protein, and causes Ca(2+) sensitization via inactivation of myosin phosphatase. The major physiological functions of Rho-kinase include contraction, migration, and proliferation in cells. These actions are thought to be related to the pathophysiological features of asthma, i.e., airflow limitation, airway hyperresponsiveness, beta-adrenergic desensitization, eosinophil recruitment and airway remodeling. Here, the roles of RhoA/Rho-kinase in the pathophysiology and treatment of asthma were investigated. In airway smooth muscle, pre-exposure to chemical mediators released from inflammatory cells markedly enhances methacholine-induced contraction without elevating intracellular concentrations of Ca(2+). This augmented responsiveness to methacholine involves the phosphorylation of myosin phosphatase targeting protein 1 (MYPT1) via Rho-kinase, however, it is attenuated by pre-treatment with Rho-kinase inhibitors such as Y-27632 and HA-1077. Airway smooth muscle contraction due to asthma-related substances such as contractile agonists and reactive oxygen species is suppressed by these Rho-kinase inhibitors. Reduced responsiveness to beta-adrenergic receptor agonists occurs via Ca(2+) sensitization, after exposure to lysophospholipids and proteases released from inflammatory cells. This beta-adrenergic desensitization is also attenuated in the presence of Y-27632. Furthermore, the proliferation of airway smooth muscle cells is elevated by Rho-kinase, however, it is markedly suppressed by Y-27632. Antigen challenges cause hyperresponsiveness and eosinophilia in the airways; however, these reactions are markedly suppressed by these Rho-kinase inhibitors. These findings indicate that RhoA/Rho-kinase is involved in the pathophysiology of asthma, and suggest that Rho-kinase inhibitors have therapeutic potential for prohibiting these features. In conclusion, RhoA/Rho-kinase is a novel target molecule for the treatment of asthma.
Insights
Rho-kinase plays a key role in asthma by promoting airway hyperresponsiveness and remodeling. Inhibiting Rho-kinase (ROCK) may offer a new therapeutic strategy for treating asthma effectively.
Area of Science:
- Cellular signaling pathways
- Respiratory medicine
- Pharmacology
Background:
- Rho-kinase (ROCK) is a downstream effector of RhoA, influencing cellular functions like contraction and proliferation.
- ROCK mediates Ca(2+) sensitization by inactivating myosin phosphatase, impacting smooth muscle tone.
- ROCK's functions are implicated in key asthma pathologies, including airway hyperresponsiveness and remodeling.
Purpose of the Study:
- To investigate the role of the RhoA/Rho-kinase pathway in asthma pathophysiology.
- To evaluate the therapeutic potential of Rho-kinase inhibitors in asthma treatment.
Main Methods:
- Assessed methacholine-induced airway smooth muscle contraction.
- Examined the effects of Rho-kinase inhibitors (Y-27632, HA-1077) on airway smooth muscle.
- Investigated beta-adrenergic desensitization and airway smooth muscle cell proliferation.
- Evaluated the impact of Rho-kinase inhibitors on antigen-induced airway hyperresponsiveness and eosinophilia.
Main Results:
- Rho-kinase inhibitors attenuated enhanced methacholine-induced contraction and airway smooth muscle contraction.
- Beta-adrenergic desensitization and airway smooth muscle cell proliferation were suppressed by Rho-kinase inhibitors.
- Antigen-induced airway hyperresponsiveness and eosinophilia were significantly reduced by Rho-kinase inhibitors.
Conclusions:
- The RhoA/Rho-kinase pathway is critically involved in the pathophysiology of asthma.
- Rho-kinase inhibitors demonstrate significant therapeutic potential for mitigating key features of asthma.
- Targeting Rho-kinase represents a novel therapeutic strategy for asthma treatment.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
